Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy
This book is a compendium of scientific articles submitted to a Special Issue of International Journal of Molecular Sciences, fostered by MDPI and curated by Dr. Annamaria Sandomenico and Dr. Menotti Ruvo from the Institute of Biostructure and Bioimaging of the National Research Council. All article...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_79601 | ||
| 005 | 20220321 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220321s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-3166-3 | ||
| 020 | |a 9783036531670 | ||
| 020 | |a 9783036531663 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-3166-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a TB |2 bicssc | |
| 100 | 1 | |a Ruvo, Menotti |4 edt | |
| 700 | 1 | |a Ruvo, Menotti |4 oth | |
| 245 | 1 | 0 | |a Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (278 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book is a compendium of scientific articles submitted to a Special Issue of International Journal of Molecular Sciences, fostered by MDPI and curated by Dr. Annamaria Sandomenico and Dr. Menotti Ruvo from the Institute of Biostructure and Bioimaging of the National Research Council. All articles underwent a rigorous peer review and were selected to highlight the properties that make monoclonal antibodies and their functional fragments some of the most useful and versatile assets in therapy and diagnosis. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Technology: general issues |2 bicssc | |
| 653 | |a porcine deltacoronavirus | ||
| 653 | |a nucleocapsid | ||
| 653 | |a monoclonal antibodies | ||
| 653 | |a neurodegenerative disorders | ||
| 653 | |a affibody molecules | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a receptor-mediated transcytosis | ||
| 653 | |a transferrin receptor | ||
| 653 | |a AL amyloidosis | ||
| 653 | |a CD38 | ||
| 653 | |a anti-CD38 MoAb | ||
| 653 | |a Daratumumab | ||
| 653 | |a Isatuximab | ||
| 653 | |a myeloma | ||
| 653 | |a BCMA | ||
| 653 | |a bispecific T-cell engager | ||
| 653 | |a antibody-drug conjugates | ||
| 653 | |a chimeric antigen receptor T-cells | ||
| 653 | |a belantamab mafodotin | ||
| 653 | |a idecabtagene vicleucel | ||
| 653 | |a JNJ-68284528 | ||
| 653 | |a Mabs | ||
| 653 | |a Antibody-Drug Conjugate | ||
| 653 | |a cancer therapy | ||
| 653 | |a drug targeting | ||
| 653 | |a payload | ||
| 653 | |a cross-linking | ||
| 653 | |a antibody fragment | ||
| 653 | |a Fab | ||
| 653 | |a scFv | ||
| 653 | |a E. coli | ||
| 653 | |a YKL-40 | ||
| 653 | |a CHI3L1 | ||
| 653 | |a monoclonal antibody | ||
| 653 | |a phage display | ||
| 653 | |a lung metastasis | ||
| 653 | |a prostate-specific membrane antigen | ||
| 653 | |a in vivo imaging | ||
| 653 | |a prostate cancer | ||
| 653 | |a glutamate carboxypeptidase II | ||
| 653 | |a NAALADase | ||
| 653 | |a immunization | ||
| 653 | |a antibody | ||
| 653 | |a protocol | ||
| 653 | |a guinea pig | ||
| 653 | |a cDNA | ||
| 653 | |a chimeric antigen receptor (CAR T) | ||
| 653 | |a universal CAR T | ||
| 653 | |a modular CAR T | ||
| 653 | |a universal immune receptor | ||
| 653 | |a CAR adaptor | ||
| 653 | |a adoptive immunotherapy | ||
| 653 | |a split CAR | ||
| 653 | |a bispecific | ||
| 653 | |a polyspecificity | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a solubility | ||
| 653 | |a aggregation | ||
| 653 | |a viscosity | ||
| 653 | |a developability | ||
| 653 | |a stability | ||
| 653 | |a affinity | ||
| 653 | |a specificity | ||
| 653 | |a protein engineering | ||
| 653 | |a self-association | ||
| 653 | |a non-specific binding | ||
| 653 | |a immunogenicity | ||
| 653 | |a antibody fragments | ||
| 653 | |a single chain | ||
| 653 | |a amyloid | ||
| 653 | |a oligomer | ||
| 653 | |a neurotoxicity | ||
| 653 | |a NUsc1 | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4985 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/79601 |7 0 |z DOAB: description of the publication |